18 completed, 9 terminated, 4 withdrawn, 2 unknown. 22 Phase 4, 5 Not applicable, 2 Phase 1, 2 Phase 3, 1 Phase 2.
Follow iodixanol: new trials by email Literature Review of iodixanol trials Research Report on iodixanol
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Preoperative Embolization of Hypervascular Head and Neck Tumors to Improve Surgical Outcomes Iodixanol, Angiogram, Arterial Embolization - Malignant Neoplasm in the Head and Neck, Metastatic Malignant Neoplasm in the Head and Neck | Phase 1 | Withdrawn | University of Washington | 2023-12-21 | 2023-12-12 | |
| Pediatric Risk of Hypothyroidism With Iodinated Contrast Media Iohexol, Iodixanol, Iopromide - Hypothyroidism | Phase 4 | Withdrawn | GE Healthcare | 2022-03-01 | 2022-04-20 | |
| Iso-Osmolar vs. Low-Osmolar Contrast Agents for Optical Coherence Tomography Iodixanol, Iohexol - Coronary Artery Disease, Contrast Media Reaction | Phase 4 | Completed | Minneapolis Heart Institute Foundation | 62 | 2021-09-30 | 2026-08-19 |
| Post-Marketing Safety Study in ST-Segment Elevation Myocardial Infarction (STEMI) Participants Undergoing Primary Percutaneous Coronary Intervention (PCI) Procedure With VISIPAQUE® as the Contrast Medium Iodixanol - Coronary Artery Disease, ST-segment Elevation Myocardial Infarction | Completed | GE Healthcare | 2755 | 2018-11-05 | 2022-01-11 | |
| A Study to Explore the Renal Safety of Visipaque Injection 320 mgI/mL in Patients With Chronic Kidney Disease Visipaque, Placebos - Chronic Kidney Diseases | Phase 4 | Terminated | GE Healthcare | 4 | 2018-02-08 | 2019-12-17 |
| Adequate Hydration Therapy Combined With Intravenous Infusion of Isosorbide Dinitrate Prevention for CIN Hydration Combined With Intravenous Infusion of Isosorbide Dinitrate, Visipaque, 0.9% sodium chloride fluid administration - Cardio-Renal Syndrome | Not applicable | Unknown | Chinese PLA General Hospital | 400 | 2016-03-01 | 2016-03-24 |
| Efficacy of Low (30ml) Versus Full Dose (100ml) Contrast CT Pulmonary Angiography in Detecting Emboli Low-Dose IV Contrast, Siemens Sensation 64-MDCT scanner., Visipaque 320 non-ionic isoosmolar contrast agent - Multiple Pulmonary Emboli | Not applicable | Withdrawn | VA Greater Los Angeles Healthcare System | 2016-01-01 | 2016-11-08 | |
| Central Venous Pressure Guided Hydration Prevention for Contrast-Induced Nephropathy hydration, Visipaque, 0.9% sodium chloride fluid administration - Cardio-Renal Syndrome | Not applicable | Completed | Chinese PLA General Hospital | 264 | 2014-02-01 | 2015-04-01 |
| Effects Contrast on Platelet Activity, Thrombosis and Fibrinolysis in Patients Undergoing Coronary Angiography Iodixanol, Ioxaglate, Bivalirudin - Coronary Artery Disease | Phase 4 | Completed | NYU Langone Health | 100 | 2013-02-01 | 2016-04-06 |
| Renal Toxicity of Iodixanol and Iopromide in Patients With Renal Dysfunction iodixanol, iopromide - Kidney Failure, Chronic | Phase 4 | Unknown | Yong Huo | 200 | 2012-04-01 | 2013-10-16 |
| Comparing Patient Comfort and Safety Between Iodixanol and Iopamidol in Patients Undergoing Peripheral Arteriography Iodixanol, Iopamidol - Drug Safety | Phase 4 | Completed | GE Healthcare | 255 | 2011-10-01 | 2014-06-11 |
| Iodixanol Versus Iopamidol in Patients Undergoing Contrast-Enhanced Computed Tomographic Imaging of Abdomen/Pelvis Iodixanol, Iopamidol - Patient Comfort and Safety | Phase 4 | Completed | GE Healthcare | 304 | 2011-05-01 | 2013-12-19 |
| Kidney Damage in Patients With Moderate Fall in eGFR Iopamidol, Iodixanol-320 - Coronary Artery Stenosis | Phase 4 | Completed | Bracco Diagnostics, Inc | 57 | 2010-11-01 | 2020-11-04 |
| Pulmonary Interstitial Lymphography in Early Stage Lung Cancer Stereotactic Body Radiation Therapy (SBRT), Computed Tomography (CT), Cyberknife - Lung Cancer, Lung Cancer Non-Small Cell Cancer (NSCLC) | Not applicable | Terminated | Stanford University | 12 | 2010-08-01 | 2018-04-17 |
| Isovue in Peripheral Digital Subtraction Angiography (DSA) iopamidol, iodixanol - Peripheral Arterial Occlusive Disease | Phase 4 | Completed | Bracco Diagnostics, Inc | 174 | 2010-04-01 | 2013-05-30 |
| Prognostic Value of Baseline Computed Tomography (CT) Perfusion Parameters of Pancreatic Cancer for Patients Undergoing Stereotactic Body Radiotherapy or Surgical Resection Stereotactic body radiotherapy, Iodixanol, Iohexol - Pancreatic Cancer | Terminated | Stanford University | 6 | 2010-03-01 | 2016-07-01 | |
| Single Dose Safety, Tolerance and Pharmacokinetic Study in Healthy Volunteers Undergoing Contrast-enhanced Abdominal Computed Tomography (CT) GE-145 (AN113111) Injection, Visipaque (iodixanol) Injection - Healthy | Phase 1 / Phase 2 | Completed | GE Healthcare | 50 | 2009-10-01 | 2012-04-05 |
| Renal Safety of Iopamidol Versus Iodixanol During Coronary Angiography in Diabetic Patients Iopamidol injection 76%, iodixanol - Chronic Renal Impairment, Diabetes Mellitus | Phase 4 | Terminated | Bracco Diagnostics, Inc | 23 | 2009-03-01 | 2012-01-26 |
| A Safety Comparison of Iopromide and Iodixanol in Renal Impaired Patients Iopromide (Ultravist), Iodixanol (Visipaque) - Kidney Failure, Chronic | Phase 4 | Completed | Chinese PLA General Hospital | 592 | 2009-02-01 | 2011-06-27 |
| Contrast-medium Induced Nephrotoxicity in Patients Undergoing Coronary Angiography - Iodixanol Versus Iopromide contrast agent (iopromide), contrast agent (iodixanol) - Chronic Renal Insufficiency, Coronary Angiography | Phase 4 | Completed | Seoul National University Bundang Hospital | 420 | 2009-02-01 | 2010-07-07 |
Showing 20 of 33. Sign in to see all of them.
Coronary Artery Disease (8) · Renal Insufficiency, Chronic (7) · Renal Insufficiency (4) · Diabetes Mellitus (3) · Cardio-Renal Syndrome (2) · Kidney Failure, Chronic (2) · Peripheral Arterial Occlusive Disease 1 (2) · Acute Kidney Injury (1) · Aortic Aneurysm, Abdominal (1) · Carcinoma, Non-Small-Cell Lung (1) · Coronary Stenosis (1) · Hypothyroidism (1) · Lung Neoplasms (1) · Mesothelioma (1) · Pancreatic Neoplasms (1)
GE Healthcare (11) · Bracco Diagnostics, Inc (4) · Chinese PLA General Hospital (3) · Guerbet (2) · Stanford University (2) · Deutsches Herzzentrum Muenchen (1) · Guangdong Provincial People's Hospital (1) · Minneapolis Heart Institute Foundation (1) · NYU Langone Health (1) · Norwegian University of Science and Technology (1) · Ospedale San Donato (1) · Seoul National University Bundang Hospital (1) · University of Edinburgh (1) · University of Washington (1) · VA Greater Los Angeles Healthcare System (1)
United States (18) · China (6) · United Kingdom (3) · Canada (2) · France (2) · Germany (2) · South Korea (2) · Belgium (1) · Italy (1) · Norway (1) · Poland (1) · Spain (1)
Lauren Lim, PharmD (2) · Veronica Reichl (2) · Albert Schoemig, MD (1) · Alberto Spinazzi, M.D. (1) · Aya Kamaya (1) · Billy W Loo, Jr, MD, PhD (1) · Binita Shah, MD, MS (1) · Bruce M. Barack, M.D. (1) · Corinne Dubourdieu, PhD (1) · Dai Yun Chen, MD (1) · Do Lim (1) · Eddie Darton, MD (1) · Emmanouil Brilakis, MD, PhD (1) · Fred Feit, MD (1) · Jean-Paul Antonini (1)
PMID 19829124, PMID 20031753, PMID 21782483, PMID 22305183, PMID 23045301, PMID 24856027, PMID 26685074, PMID 29751980, PMID 30054906
2016 (1)